Wanbang Biopharma Slumps After Shenzhen Stock Exchange Puts It Under Key Monitoring

Wanbang Biopharma fell by its daily limit on July 20, closing at 53.30 yuan per share with a market value of 4.966 billion yuan, after the Shenzhen Stock Exchange said on July 17 it would closely monitor the stock for unusually sharp price swings, according to Jiemian News. The company said its prior disclosures needed no additions or corrections and that it had no undisclosed information to report. In a July 16 after-hours filing, Wanbang Biopharma also denied media and forum claims that it was advancing a core pipeline drug or had signed new drug cooperation agreements, calling the reports false. It said rumors about a sharp jump in first-half 2026 earnings were also untrue, as it had not disclosed first-half results or issued a profit warning. Jiemian News reported that the stock rose 183.01% from June 29 to July 16, far outpacing the broader market. The article said the new-drug cooperation and innovation-drug development chatter actually referred to Wanbangde, a company with a similar name. Wanbangde disclosed agreements with Haixiang Pharmaceutical in early January 2026 and early June 2026, while saying its phase II/III registrational trial of a class 2 drug had enrolled 200 patients. Wanbang Biopharma’s share surge was largely the result of the mix-up. Separately, Wanbang Biopharma’s own earnings have weakened. Founded in 2006 as an early entrant in China’s CRO market, the company reported revenue below 400 million yuan at its previous peak. Revenue fell to 274 million yuan in 2025 from 36.4345 million yuan in net profit, and first-quarter 2026 revenue was 30.5413 million yuan, with net profit slipping to a loss of 261,800 yuan. Jiemian News also said China’s generic-drug CRO sector is consolidating as competition intensifies. At the end of June 2026, Wanbang Biopharma proposed buying a 75.52% stake in Saidesheng Pharmaceutical for 302 million yuan. Saidesheng reported 2025 revenue above 100 million yuan and net loss of 2.6802 million yuan. The deal values Saidesheng’s equity at 402 million yuan, a 397.06% premium, and includes profit targets of at least 30 million yuan, 35.5 million yuan and 43.5 million yuan in 2026, 2027 and 2028, respectively.